KHK 6640

Drug Profile

KHK 6640

Alternative Names: KHK-6640

Latest Information Update: 12 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Immunas Pharma
  • Developer Kyowa Hakko Kirin
  • Class Monoclonal antibodies; Nootropics
  • Mechanism of Action Amyloid beta-protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Alzheimer's disease

Most Recent Events

  • 01 May 2017 Kyowa Hakko Kirin Pharma completes a phase I trial in Alzheimer's disease in Belgium, Finland, the Netherlands, Serbia and Sweden (NCT02127476)
  • 01 Mar 2017 Kyowa Hakko Kirin initiates a phase I trial in Alzheimer's disease in Japan (NCT03093519)
  • 01 Sep 2016 Kyowa Hakko Kirin completes a phase-I clinical trial in Alzheimer's disease in Japan (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top